Quantitative neuromuscular MRI to track muscle fat in demyelinating and hereditary neuropathies
Official title: Longitudinal Quantitative Neuromuscular MRI Evaluation in Patients With Acquired and Hereditary Neuropathy
Run by Assistance Publique Hopitaux De Marseille · NCT06845644 · Data updated 2026-11-12
This project uses MRI and ultrasound to measure muscle fat and other imaging markers in adults with inherited or acquired demyelinating neuropathies to see if the scans can track disease changes over time.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Assistance Publique Hopitaux De Marseille Academic / other |
| Locations | 1 site (Marseille) |
| Status | Recruiting |
| Started | May 23, 2025 |
| Main results expected | May 23, 2027 |
| Study ends | May 2028 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT06845644 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18–80 with genetically confirmed CMT1A or transthyretin mutations, or with a typical acquired demyelinating neuropathy (e.g., CIDP or anti‑MAG), who can tolerate MRI, have given informed consent, and are covered by a social security scheme.
✕Probably not a fit
Patients with other coexisting peripheral neuropathies, active alcohol or substance abuse, contraindications to MRI (for example pacemakers, certain metal implants, or severe claustrophobia), or who cannot undergo MRI due to severe disability are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with Charcot–Marie–Tooth type 1A, hereditary transthyretin amyloid neuropathy, or acquired demyelinating neuropathies will undergo quantitative neuromuscular MRI and neuromuscular ultrasound at baseline and at scheduled follow-up visits to measure intramuscular fat fraction and other imaging biomarkers. MRI provides three-dimensional, non‑ionizing differentiation between muscle and fat, enabling objective in vivo measurement of structural changes that complement clinical and electrophysiological scores. The protocol standardizes image acquisition and quantitative analysis to compare biomarker trajectories across neuropathy types and over time. Results are intended to support imaging endpoints for monitoring progression or response in future therapeutic studies.
Why it matters
Potential benefit: If successful, this could provide reliable imaging biomarkers to track disease progression and help guide or measure responses to therapies in neuropathy patients.
How similar studies have gone: Quantitative neuromuscular MRI has shown promise and utility in several neuromuscular disorders as a biomarker, though longitudinal data specifically in these demyelinating and hereditary neuropathies remain relatively limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female between 18 and 80 years of age, * Patients who have freely given their consent to participate in this study, * Patient with genetically confirmed hereditary CMT neuropathy * or patient with an acquired demyelinating neuropathy such as typical PIDC or anti-MAG of typical form * or a patient with a genetically confirmed pathogenic mutation in the transthyretin (TTRn) gene, * Patients who are beneficiaries or entitled beneficiaries of a social security scheme. Exclusion Criteria: * Patients with co-morbidity or a history of other peripheral neuropathy, * Patients with alcohol or psychoactive substance abuse, * Patients with contraindications to MRI exploration: claustrophobia, pacemakers, Holter systems, IUDs, metal surgical clips, metal prostheses or implants (or other metal foreign bodies), * Patient unable to perform the MRI due to severe handicap, * Patient in a period of exclusion from another research protocol at the time of signing the consent/non-opposition form, * Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women), * Persons who cannot read and understand the French language well enough to be able to give their consent to participate in research.
Where it's running
-
Assistance - Publique Hôpitaux de Marseille
Marseille, France Recruiting
Study contacts
- Study coordinator: Etienne FORTANIER, MD
- Email: etienne.fortanier@ap-hm.fr
- Phone: 04 91 38 65 79
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Intensive rehab plus tendon vibration to improve balance in adults with CMT1A
This study tests whether a multidisciplinary rehabilitation program combined with tendon vibratory stimulation can improve functional balance in adults with Charcot-Marie-Tooth disease type 1A.
-
First human testing of EDK060 in adults with CMT1A.
This trial will test whether different doses of the experimental drug EDK060 are safe and how the body processes them in adults with CMT1A.
-
Evaluating EN001 for Charcot-Marie-Tooth Disease Type 1A
This study is testing a new treatment called EN001 to see if it is safe and effective for people with Charcot-Marie-Tooth Disease Type 1A.
-
High-tech rehabilitation program for adults with chronic neuromuscular diseases
This trial will test whether a high-tech rehab program using robotic systems, virtual reality, and balance platforms works as well as traditional rehab to reduce fatigue and improve function in adults with chronic neuromuscular diseases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.